{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:52:47Z","timestamp":1761864767490,"version":"3.44.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,17]]},"DOI":"10.7759\/cureus.92515","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T09:05:41Z","timestamp":1758099941000},"source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapy-Induced Hepatitis Mimicking Sclerosing Cholangitis in a Patient With Metastatic Triple-Negative Breast Cancer"],"prefix":"10.7759","author":[{"given":"Mohammed","family":"Khizer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Faize","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeed","family":"Omar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes WD","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010, 363:1938-48. 10.1056\/NEJMra1001389","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent R","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, et al.. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007, 13:4429-34. 10.1158\/1078-0432.CCR-06-3045","journal-title":"Clin Cancer Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3001","article-title":"Breast cancer immunotherapy: facts and hopes","volume":"24","author":"Emens LA","year":"2018","unstructured":"Emens LA. Breast cancer immunotherapy: facts and hopes. Clin Cancer Res. 2018, 24:511-20. 10.1158\/1078-0432.CCR-16-3001","journal-title":"Clin Cancer Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid P","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, et al.. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018, 379:2108-21. 10.1056\/NEJMoa1809615","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpt.2023.06.002","article-title":"Efficacy and safety of first-line treatment for metastatic triple-negative breast cancer: a network meta-analysis","volume":"2","author":"Shi M","year":"2024","unstructured":"Shi M, Li Z, Shen G, et al.. Efficacy and safety of first-line treatment for metastatic triple-negative breast cancer: a network meta-analysis. Cancer Pathog Ther. 2024, 2:81-90. 10.1016\/j.cpt.2023.06.002","journal-title":"Cancer Pathog Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes J","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, et al.. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020, 396:1817-28. 10.1016\/S0140-6736(20)32531-9","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang Y","year":"2019","unstructured":"Wang Y, Zhou S, Yang F, et al.. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019, 5:1008-19. 10.1001\/jamaoncol.2019.0393","journal-title":"JAMA Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2019.07.009","article-title":"Checkpoint inhibitor-induced liver injury: a novel form of liver disease emerging in the era of cancer immunotherapy","volume":"36","author":"Zen Y","year":"2019","unstructured":"Zen Y, Yeh MM. Checkpoint inhibitor-induced liver injury: a novel form of liver disease emerging in the era of cancer immunotherapy. Semin Diagn Pathol. 2019, 36:434-40. 10.1053\/j.semdp.2019.07.009","journal-title":"Semin Diagn Pathol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31001","article-title":"Letter to the Editor: Bone health and denosumab treatment in autoimmune liver diseases: a possible involvement of physical activity","volume":"71","author":"Sugiyama T","year":"2020","unstructured":"Sugiyama T. Letter to the Editor: Bone health and denosumab treatment in autoimmune liver diseases: a possible involvement of physical activity. Hepatology. 2020, 71:1131-2. 10.1002\/hep.31001","journal-title":"Hepatology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2018-205143","article-title":"Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists' perspective","volume":"71","author":"Karamchandani DM","year":"2018","unstructured":"Karamchandani DM, Chetty R. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists' perspective. J Clin Pathol. 2018, 71:665-71. 10.1136\/jclinpath-2018-205143","journal-title":"J Clin Pathol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/394707-immunotherapy-induced-hepatitis-mimicking-sclerosing-cholangitis-in-a-patient-with-metastatic-triple-negative-breast-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T09:05:41Z","timestamp":1758099941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/394707-immunotherapy-induced-hepatitis-mimicking-sclerosing-cholangitis-in-a-patient-with-metastatic-triple-negative-breast-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.92515","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,17]]}}}